Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Cryoport to Present at 2016 Cell & Gene Meeting on the Mesa

Posted on: 30 Sep 16

IRVINE, Calif., Sept. 29, 2016 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences, announced today that Dr. Mark Sawicki, Chief Commercial Officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, to be held October 5-7 in La Jolla, California.

This event is the largest partnering meeting organized specifically for the cell and gene therapy and regenerative medicine sector, providing the opportunity for participants to establish key relationships and accelerate business development.

Organized by ARM and the Sanford Consortium for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is a three-day conference featuring three distinct parts: the program's two-day Partnering Forum, a Public Forum lecture and a full-day Scientific Symposium. At the Partnering Forum, held October 5 and 6, industry executives will lead in-depth, interactive panels and workshops to discuss critical commercial issues facing the sector today.

This year's event will attract more than 800 attendees, including senior executives from leading cell therapy, gene therapy and tissue engineering companies worldwide, large pharma and biotech, institutional investors, academic research institutions, patient foundations and disease philanthropies, life science media and more.

The following are specific details regarding Cryoport's presentation at the conference:


2016 Cell & Gene Meeting on the Mesa – Partnering Forum

Date / Time:

Wednesday, October 5 at 5 p.m.


La Jolla Ballroom 2


Estancia La Jolla Hotel & Spa


9700 North Torrey Pines Road, La Jolla, CA 92037

A live video webcast of all company presentations will be available at: and will also be published on ARM's website shortly after the event.

Please visit for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Laura Parsons at and interested media should contact Lyndsey Scull at

About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproductive medicine. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Cryoport is dedicated to

simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;

delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and

providing vital information that provides peace of mind throughout the life of each logistics process

For more information, visit To download Cryoport's investor relations app, which offers access to SEC documents, press releases, videos, audiocasts and more, please click to download from your iPhone and iPad or Android mobile device.

Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2015. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Editor's Details

Mike Wood

Last updated on: 30/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.